Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Abstract

The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).

Dependencies are inferred from the claim text.